Omegacin should be used in pregnant women or women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment. The safety of Omegacin in pregnant women has not been established.
It is advisable to avoid using Omegacin in lactating mothers. If use of Omegacin is judged to be essential, breastfeeding must be discontinued during treatment. It has been reported that Omegacin is excreted in breast milk in animal studies (rats).